Open AccessDaratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature
Author(s) -
Matthew Lee,
Beth A. Martin,
Haifaa Abdulhaq
Publication year - 2022
Publication title -
case reports in hematology
Language(s) - English
Resource type - Journals
eISSN - 2090-6579
pISSN - 2090-6560
DOI - 10.1155/2022/8331766
Subject(s) - medicine , plasmablastic lymphoma , lenalidomide , vincristine , regimen , prednisone , plasmacytoma , bortezomib , etoposide , oncology , cyclophosphamide , lymphoma , gastroenterology , dexamethasone , chemotherapy , multiple myeloma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom